Current Listing of Claims:

This listing of claims, with markings to show any changes made, will replace all prior versions, and listings, of claims in the application.

1. (Withdrawn-Currently Amended) A method for treating anxiety in a patient in need of said treatment comprising orally administering to said patient as an active ingredient, an anti-anxiety compound of the formula



I

or a pharmaceutically acceptable salt thereof,

at a daily oral dosage of from about 50 to about 250 mg, ~~with~~ wherein said daily oral ~~dose having~~ dosage comprises a first portion of the active ingredient in ~~an~~ a rapid release form and the remaining portion of said active ingredient in a sustained release form, ~~said proportion~~ and wherein the amount of said active ingredient in the rapid release form ~~administered being~~ is from about 1 to about 4 times ~~14~~ the weight of the ~~portion administered~~ active ingredient in the sustained release form.



2. (Withdrawn-Currently Amended) The method of claim 1, wherein the daily oral dosage ~~dose~~ is administered in from 1 to 3 administrations per day.

3. (Withdrawn-Currently Amended) The method of claim 1, wherein said active ingredient is administered as ~~2~~ tablets.

4. (Withdrawn-Currently Amended) The method of claim 2, wherein for each of said ~~separate~~ administrations, the ~~2~~ sustained release portion is administered in combination with the rapid release portion.

5. (Withdrawn-Currently Amended) The method of claim 4, wherein the daily ~~dose~~ oral dosage of said anti-anxiety compound is from about 120 to about 240 mg.

6. (Withdrawn-Currently Amended) The method of claim 5, wherein ~~in~~ for each of said administrations the ~~proportion~~ amount of said active ingredient in the rapid release portion ~~form~~ is about ~~2.5~~ 2.5 to 3.5 times the weight of the ~~portion~~ active ingredient in the ~~slow~~ sustained release portion.

7. (Withdrawn-Currently Amended) The method of claim 3, wherein in each of said administrations the ~~slow~~ sustained release portion is administered together with the rapid release portion ~~portions~~.

8. (Withdrawn-Currently Amended) The method of claim 7, wherein in each of said administrations, the ~~slow~~ sustained release portion and the rapid release portion are administered in a single tablet.

9. (Withdrawn-Currently Amended) The method of claim 8, wherein said tablet contains the active ingredient in rapid release form in an amount of about 3 times the weight of the active ingredient ~~slow~~ in sustained release form.

10. (Withdrawn-Currently Amended) The method of claim 9, wherein the ~~tablets administered contain~~ tablet contains about 10 mg of the active ingredient in ~~its~~ sustained release form and about 30 mg of the active ingredient in ~~its~~ rapid release form.

11. (Withdrawn) The method of claim 9 wherein the ~~tablets administered contain~~ tablet contains about 30 mg of the active ingredient in ~~its~~ sustained release form and about 90 mg of the active ingredient in ~~its~~ rapid release form.

12. (Currently Amended) A pharmaceutical oral unit dosage form comprising two separate compartments each containing a composition ~~comprised~~ which comprises as a pharmaceutically active ingredient ~~selected from the group consisting of the~~ a compound of the formula



I

~~and~~ or a pharmaceutically acceptable salt thereof

~~in a mixture with~~ and a pharmaceutically acceptable carrier, said active ingredient being present in the unit dosage form in an amount of from about 50 to about 250 mg, with the amount of said active ingredient in the first compartment being from about 1 to about 4 times the weight of said active ingredient in the second compartment, and wherein the composition ~~11~~ in the first compartment ~~being~~ is adapted for rapid release of said active ingredient contained therein and the composition in the second compartment ~~having~~ has incorporated therein a hydrophilic polymeric matrix which causes sustained release of the active ingredient in the second compartment.



13. (Currently Amended) The unit dosage form of claim 12 wherein the oral unit dosage form is a tablet.

14. (Currently Amended) The unit dosage form of claim 13, wherein the composition has a particle ~~a~~ size diameter of less than 250 microns.

15. (Currently Amended) The unit dosage form of claim 14, wherein the polymeric matrix is ~~a~~ hydroxypropyl methyl cellulose.

16. (Original) The unit dosage form of claim 15, wherein the pharmaceutically acceptable carrier in each of said compartments is fast flow lactose.

17. (Original) The unit dosage form of claim 14, wherein the active ingredient is present in the unit dosage form in an amount of from about 80 to about 240 mg.

18. (Currently Amended) The unit dosage form of claim 17, wherein the active ingredient is present ~~a~~ in the unit dosage form in an amount of from about 120 to about 240 mg.

19. (Currently Amended) The unit dosage form of claim 18, wherein the amount of active ingredient ~~is~~ in the ~~a~~ rapid release ~~portion~~ composition is ~~in an amount of~~ about 2.5 to ~~5~~ 3.5 times the weight of the active ~~3~~ ingredient in the sustained release composition ~~portion~~.

20. (Currently Amended) The unit dosage form of claim 19, wherein the tablet contains about 30 mg ~~a~~ of the active ingredient in the sustained release ~~form~~ composition and about 90 mg of the active ~~3~~ ingredient in the rapid release composition ~~form~~.

21. (Currently Amended) The unit dosage form of claim 20 wherein the tablet contains from about 10 mg of the active ingredient in the sustained release ~~form~~ composition and about 30 mg of the active ingredient in the rapid release composition ~~form~~.